Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).
6d
Hosted on MSNGSK’s Penmenvy meningococcal vaccine gains FDA approvalThe studies confirmed that the vaccine has a safety profile consistent with the licensed meningococcal vaccines of GSK. The ...
The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...
4d
HealthDay on MSNFDA Approves More Broadly Protective Meningococcal VaccineThe U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active ...
GSK (GSK) plc announced that the Food and Drug Administration has approved Penmenvy for use in individuals aged 10 through 25 years. The ...
GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for ...
Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...
Tony Wood, Chief Scientific Officer, GSK, said: "We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by ...
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
葛兰素史克公司 (LSE/NYSE: GSK) 宣布,美国食品药品监督管理局 (FDA) 已批准 PENMENVY(脑膜炎球菌 A、B、C、W 和 Y 组疫苗)供 10 至 25 岁人群使用。该疫苗针对通常导致侵袭性脑膜炎球菌病 (IMD) ...
The approvals come as Robert F. Kennedy Jr.—who has been critical of vaccines—takes leadership of the Department of Health ...
GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results